{
    "nct_id": "NCT04794699",
    "official_title": "An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors",
    "inclusion_criteria": "* Participant must be at least 18 years of age\n* Advanced or metastatic solid tumor that has progressed on at least one prior line of treatment or is intolerant to additional effective standard therapy\n* Have evidence of homozygous loss of MTAP or MTAP deletion\n* Willing to undergo paired fresh biopsy (pre- and post-treatment) procedure. Exceptions may be made for feasibility and safety concerns\n* Measurable disease\n* ECOG performance status <= 1\n* Adequate organ function\n* Able to swallow and retain orally administered study treatment\n* Recovery from acute effects of prior therapy\n* Able to comply with contraceptive/barrier requirements\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known symptomatic brain metastases\n* Known primary CNS malignancy\n* Current active liver or biliary disease\n* Impairment of gastrointestinal (GI) function\n* Active uncontrolled infection\n* Clinically significant cardiac abnormalities\n* Previous treatment with a MAT2A inhibitor and / or PRMT inhibitor or sacituzumab govitecan\n* Systemic anti-cancer therapy or major surgery within 4 weeks prior to study entry\n* Radiation therapy within 2 weeks prior to study entry\n* Prior irradiation to >25% of the bone marrow\n* Current use or anticipated need for food or drugs that are known strong CYP3A4/5 inhibitors or inducers\n* Currently receiving another investigational study drug.\n* Known or suspected hypersensitivity to IDE397/excipients or components",
    "miscellaneous_criteria": ""
}